ea0022p625 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010
van der Lely Aart-Jan
, Bernabeu Ignacio
, Cap Jan
, Caron Philippe
, Colao Annamaria
, Lesage Catherine
, Marek Josef
, Neggers Sebastian
, Birman Pascal
Recent studies have shown that the co-administration of lanreotide (lan) with pegvisomant (peg) was able to normalise IGF1 secretion in patients with acromegaly who were partial responders to somatostatin analogues (SSAs).Fifty seven subjects with acromegaly (mean age 51.6±12.7 years) not previously controlled by SSAs (either treated by SSAs for at least 6 months with IGF1 > ULN, or on peg for at least 3 months) with IGF1 > 1.2 ULN (n...